Operator of a biotechnology company intended to expand the therapeutic potential of in vivo RNA-based therapies through proprietary targeted delivery systems. The company's platform comprises targeted lipid nanoparticles to help off-the-shelf immunotherapies with tight control of dosage and activity of engineered cells, thereby enabling researchers to advance transformative products for oncology, fibrosis and inflammation-related diseases.